Just reading back over this and one paragraph in particular sums up exactly what they have in relation to the use of cardiocel in valve repair.
"For the first time all aspects to produce an ideal universal bioprosthetic substitute for cardiovascular application in both paediatric and adult patients has been met"
This is what surgeons have been waiting for, IMO this invention will be huge.
- Forums
- ASX - By Stock
- AVR
- EACTS 2014
EACTS 2014, page-41
-
-
- There are more pages in this discussion • 41 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
|
|||||
Last
$17.91 |
Change
-0.090(0.50%) |
Mkt cap ! $344.2M |
Open | High | Low | Value | Volume |
$18.00 | $18.10 | $17.75 | $74.32K | 4.151K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 681 | $17.90 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$18.25 | 100 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 681 | 17.900 |
1 | 1 | 17.800 |
1 | 443 | 17.700 |
1 | 26 | 17.650 |
1 | 200 | 17.560 |
Price($) | Vol. | No. |
---|---|---|
18.250 | 100 | 1 |
18.300 | 150 | 1 |
18.500 | 43 | 1 |
18.690 | 550 | 1 |
18.750 | 143 | 1 |
Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online